- Home
- HFBL vs NRXS Comparison
HFBL vs NRXS Comparison
Compare HFBL & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | HFBL | NRXS |
|---|---|---|
| Founded | 1924 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.3M | 78.9M |
| IPO Year | 2010 | 2023 |
Fundamental Metrics
Financial Performance| Metric | HFBL | NRXS |
|---|---|---|
| Price | $25.99 | $6.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 2.0K | ★ 80.5K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | 7.69 | ★ 22.13 |
| EPS | ★ 1.55 | N/A |
| Revenue | $1,303,000.00 | ★ $3,569,282.00 |
| Revenue This Year | N/A | $172.91 |
| Revenue Next Year | N/A | $115.71 |
| P/E Ratio | $16.15 | ★ N/A |
| Revenue Growth | 17.49 | ★ 32.89 |
| 52 Week Low | $13.45 | $2.21 |
| 52 Week High | $28.00 | $9.33 |
Technical Indicators
Market Signals| Indicator | HFBL | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 59.03 | 42.39 |
| Support Level | $21.08 | $6.04 |
| Resistance Level | $28.00 | $7.37 |
| Average True Range (ATR) | 0.42 | 0.24 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 37.54 | 43.89 |
Price Performance
Historical ComparisonAbout HFBL Home Federal Bancorp Inc. of Louisiana
Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).